DDInter119 DDInter147
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations.
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lansoprazole
Axitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sodium citrate
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Axitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Axitinib {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Axitinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Axitinib may cause a minor interaction that can limit clinical effects when taken with Sodium citrate
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Axitinib may lead to a major life threatening interaction when taken with Atazanavir
Axitinib may lead to a major life threatening interaction when taken with Lomitapide